{
  "pmcid": "10364863",
  "sha256": "e6b7b5b3f47cd8f204a9032c5d4b8d642f88e4294f06b500aa02524872d1fde2",
  "timestamp_utc": "2025-11-09T23:06:11.440043+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.982945454545458,
    "reading_ease": 42.29841818181819,
    "word_count": 264
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Prognostic Value of PAM-50 in Local Recurrence Risk: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "The ABCSG-8 trial, a randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were postmenopausal women with endocrine receptor-positive breast cancer who underwent breast-conserving surgery."
      },
      "Intervention": {
        "score": 2,
        "evidence": "compared 5 years of tamoxifen with 2 years of tamoxifen followed by 3 years of anastrozole."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to assess the prognostic value of the PAM-50-based 46-gene assay for local recurrence risk in postmenopausal women with hormone receptor-positive breast cancer."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was local recurrence risk over a median follow-up of 10.8 years."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was stratified by treatment group, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Tumour blocks from 1204 patients were analysed using the PAM-50 assay."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 1204 patients, 1034 received radiotherapy."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Patients with a low ROR score (<57) had significantly lower local recurrence rates at 5 years (0.1% vs. 2.2%; SHR 17.18, 95% CI 2.06 to 142.88; p=0.009) and 10 years (0.9% vs. 3.8%; SHR 4.76, 95% CI 1.72 to 13.17; p=0.003)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT00291759"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}